FridayJan 22, 2021 11:45 am

Combat Sports Turn to Psychedelics as a Potential Treatment for Brain Injuries

If you watch a lot of combat sports, you probably know that fighters take a risk every time they step into the ring. This is because fighters know, whether they’re in the UFC Octagon or a typical boxing ring, they’re going to get hit in the head. It doesn’t matter what causes the hit —an elbow, knee, foot or fist — the brain still suffers trauma. Despite strides that have been made in research to understand why and how trauma is caused, as well as the long-term impact of said trauma, much about brain injuries remains unknown. Currently, new research…

Continue Reading

ThursdayJan 21, 2021 3:15 pm

Local Legislators in Massachusetts Unanimously Vote to Decriminalize Psychedelics

Last week, local legislators in Massachusetts unanimously confirmed their support for a resolution that would decriminalize various psychedelics. The Somerville City Council heard the testimony of two individuals who had benefitted personally from the use of psychedelics therapeutically before approving the measure in a 9-0 vote. This measure was also backed by the mayor. In addition to this, some council members debated the possible medical value of psychedelic substances, especially in mental health issues, as well as the failures of the drug war. In a written statement to legislators, the Heroic Hearts Project, Bay Staters for Natural Medicines and Decriminalize…

Continue Reading

WednesdayJan 20, 2021 2:15 pm

Cybin Inc. (NEO: CYBN) Announces Partnership with Neurotech Pioneer to Leverage Innovative Technology for Psychedelic Therapeutics

CYBN partners with pioneer company focused on exploring, quantifying the human mind Innovative Flow technology adds exciting dimension to Cybin’s commitment to develop breakthrough treatments for mental health disorders Innovative technology opens new frontier in psychedelic therapeutics Cybin (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is partnering with neurotech pioneer HI, LLC dba Kernel to quantify brain activity in real time during psychedelic experiences (https://ibn.fm/3AG5G). CYBN plans to do this by leveraging Kernel Flow, Kernel’s breakthrough technology, for its upcoming clinical work. “Access to Kernel’s innovative Flow technology adds another exciting dimension to…

Continue Reading

WednesdayJan 20, 2021 2:00 pm

Researchers to Test Virtual Psychedelics on AI to Help Understand Effects on Human Brains

While psychedelics gain popularity across the media through various clinical trials and research studies, it is important to remember that there is still a lot about them that we don’t know, including how they cause strange hallucinations and how they affect the brain. Because psychedelics cannot be easily tested on humans, researchers from the University of Geneva and Imperial College London are working on testing virtual psychedelics on artificial intelligence (“AI”) algorithms. This will help researchers learn more about psychedelic substances while also exploring how artificial intelligence responds to a substance that is known to influence the brain of humans.…

Continue Reading

WednesdayJan 20, 2021 2:00 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Commences Research into Psilocybin-Based Active Treatments

Pure Extracts commences study into psilocybin-based active treatments Study set to be carried out at Toronto Institute of Pharmaceutical Technology, supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregor Study will delve into carrying out conformity testing, stability testing for psilocybin products thereby commencing the R&D that will ultimately take place at Pure Extracts’ purpose-built research space at its facility in British Columbia Functional mushroom, psychedelic drug market forecast to grow to value of $6.85 billion by 2027 Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company, recently announced that it had commenced a study into…

Continue Reading

TuesdayJan 19, 2021 10:00 am

How the Psychedelics Industry Differs from the Cannabis Industry

Psychedelics seem to have gotten quite a boost last year when Oregonians and DC voters voted to decriminalize psychedelics. While some analysts propose that this is only the beginning for the market’s growth, and that it will be similar to that of the cannabis market, this analysis has no data to its claim. It should be noted that apart from their legality, the two substances have little in common. Comparing psychedelics to marijuana is also difficult, considering psychedelics are made up of hundreds of molecules, plants and substances while marijuana is encompassed in one plant genus. Even an individual describing…

Continue Reading

ThursdayJan 14, 2021 10:00 am

Are Psychedelic Retreats a Possibility in the US?

In the recent past, psychedelics have moved into mainstream media, which has revealed a lot about the potential benefits various psychedelics such as LSD, MDMA, ketamine and psilocybin possess. In the United States, the state of Oregon became the first state in the country to allow the therapeutic use of psychedelic mushrooms while also decriminalizing psilocybin in the state. Voters in Washington, DC, also approved a ballot measure to decriminalize the use of hallucinogenic mushrooms during the November elections. While this is progress, the aforementioned psychedelic drugs and other psychedelic substances are still illegal in the country and in many…

Continue Reading

WednesdayJan 13, 2021 2:15 pm

Research Shows Ketamine Helps Major Depressive Disorder Patients Adjust How They Perceive Reality

New research indicates that brain signals that are linked to neural plasticity may be used to explain the quick antidepressant effects that ketamine possesses. The research findings, which were reported in the “European Neuropsychopharmacology” journal, show that ketamine may help reduce depression by overriding an individual’s insensitivity to prediction error. Lead researcher Rachael Sumner explained that ketamine had the potential to not only treat but also help researchers understand depression better. This is mainly because ketamine works differently when compared to ordinary antidepressants. Sumner, who is a School of Pharmacy postdoctoral research fellow from the University of Auckland, explained that…

Continue Reading

TuesdayJan 12, 2021 2:00 pm

Could Canada Be the Next Country to Legalize Psychedelics?

Canada has made significant strides in its health policies, having allowed psychedelics to be administered to four cancer patients in their end-of-life treatments, and established and implemented a health-care program that’s publicly funded, in addition to becoming the first G7 nation to legalize marijuana in 2018. While there’s a lot the country can be commended for, some of the regulations that govern restricted substances are out-of-date. In a bid to change that, a few patients along with therapists and doctors have been allowed to use psilocybin, with the country’s federal agency looking into amending some of the existing policies, which…

Continue Reading

TuesdayJan 12, 2021 11:04 am

Health Canada Grants Selected Physicians Access to Psilocybin Mushrooms as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Dives into Functional Mushroom Market

Health Canada recently granted psilocybin testing access to selected physicians Psilocybin mushrooms shown to help patients suffering from addiction, mental health issues Pure Extracts’ ’Pure Mushrooms’ and ‘Pure Pulls’ branded products expected to be available by end of Q1 2021 In a recent virtual townhall, Canadian Health Minister Patty Hajdu disclosed that the Canadian government has recently granted access to psilocybin or “psychedelic” mushrooms to several physicians for use in patients with addiction and/or mental health issues (https://ibn.fm/j9ZAO). In line with anticipated legislation expected to loosen restrictions on psilocybin mushrooms, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a Canadian…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050